Serum complement C3 strongly correlates with whole-body insulin sensitivity in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 35, Issue 1, 2017, Pages 18-23

  Ursini, Francesco ^a   D'Angelo, Salvatore ^b   Russo, Emilio ^a   Arturi, Franco ^a   D'Antona, Lucia ^a   Bruno, Caterina ^a   Naty, Saverio ^a   De Sarro, Giovambattista ^a   Olivieri, Ignazio ^b   Grembiale, Rosa Daniela ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SAN CARLO HOSPITAL   (Italy)

Author keywords

Complement C3; Insulin sensitivity; Rheumatoid arthritis

Indexed keywords

COMPLEMENT COMPONENT C3; GLUCOSE BLOOD LEVEL; INSULIN; C REACTIVE PROTEIN;

AGED; BLOOD; BODY MASS; COMPLICATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; RHEUMATOID ARTHRITIS; RISK FACTOR; WAIST CIRCUMFERENCE; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; INSULIN SENSITIVITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

AGED; ARTHRITIS, RHEUMATOID; BLOOD GLUCOSE; BODY MASS INDEX; COMPLEMENT C3; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 85013213532     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. van HALM VP, PETERS MJ, VOSKUYL AE et al.: Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68: 1395-400.
2. LINDHARDSEN J, AHLEHOFF O, GISLASON GH et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-34.
3. VANDHUICK T, ALLANORE Y, BORDERIE D et al.: Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort. Clin Exp Rheumatol 2016; 34: 58-67.
4. INNALA L, MOLLER B, LJUNG L et al.: Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011; 13: R131.
5. MULNIER HE, SEAMAN HE, RALEIGH VS et al.: Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 2008; 51: 1639-45.
6. JIANG P, LI H, LI X: Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 2015; 33: 115-21.
7. URSINI F, RUSSO E, D'ANGELO S et al.: Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study. Medicine (Baltimore) 2016; 95: e2552.
8. WEYER C, BOGARDUS C, MOTT DM, PRATLEY RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
9. MARTIN BC, WARRAM JH, KROLEWSKI AS, BERGMAN RN, SOELDNER JS, KAHN CR: Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340: 925-9.
10. KARROWNI W, LI Y, JONES PG et al.: Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2013; 33: 2245-51.
11. EDDY D, SCHLESSINGER L, KAHN R, PESKIN B, SCHIEBINGER R: Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 2009; 32: 361-6.
12. ONAT A, HERGENC G, TURKMEN S, YAZICI M, SARI I, CAN G: Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation. Me-tabolism 2006; 55: 445-52.
13. TUOMILEHTO J, SCHWARZ P, LINDSTROM J: Long-term benefits from lifestyle interventions for type 2 diabetes prevention: time to expand the efforts. Diabetes Care 2011; 34 (Suppl. 2): S210-214.
14. CHURCH TS, LAMONTE MJ, BARLOW CE, BLAIR SN: Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med 2005; 165: 2114-20.
15. BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803.
16. DeFRONZO RA, TOBIN JD, ANDRES R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-223.
17. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
18. MATSUDA M, DeFRONZO RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
19. SVENSON KL, POLLARE T, LITHELL H, HALLGREN R: Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988; 37: 125-30.
20. DESSEIN PH, JOFFE BI: Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-75.
21. POPA C, NETEA MG, van RIEL PL, van der MEER JW, STALENHOEF AF: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007; 48: 751-62.
22. HUANG Q, TAO SS, ZHANG YJ et al.: Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Clin Rheumatol 2015.
23. ABELLA V, SCOTECE M, CONDE J et al.: Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res 2014; 2014: 343746.
24. WASKO MC, McCLURE CK, KELSEY SF, HUBER K, ORCHARD T, TOLEDO FG: Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia 2015.
25. YASAR BILGE NS, KASIFOGLU N, KASIFOGLU T, SAHIN F, GONULLU E, KORKMAZ C: The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naive to disease-modifying antirheumatic drugs. Int J Rheum Dis 2015.
26. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA, LLORCA J: Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann NY Acad Sci 2010; 1193: 153-9.
27. BURSKA AN, SAKTHISWARY R, SATTAR N: Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: a systematic review and metaanalysis. PLoS One 2015; 10: e0128889.
28. URSINI F, RUSSO E, LETIZIA HRIBAL M et al.: Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) 2015; 94: e888.
29. URSINI F, MAURO D, NATY S, GAGLIARDI D, GREMBIALE RD: Improvement in insulin resistance after short-term treatment with abatacept: case report and short review. Clin Rheumatol 2012; 31: 1401-2.
30. SCHULTZ O, OBERHAUSER F, SAECH J et al.: Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010; 5: e14328.
31. CHEN DY, CHEN YM, HSIEH TY, HSIEH CW, LIN CC, LAN JL: Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther 2015; 17: 52.
32. URSINI F, GREMBIALE A, NATY S, GREMBIALE RD: Serum complement C3 correlates with insulin resistance in never treated psoriatic arthritis patients. Clin Rheumatol 2014; 33: 1759-64.
33. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
34. WHO: Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. In. Edited by IDF; W. Geneva, Switzerland 2006.
35. KERNAN WN, INZUCCHI SE, VISCOLI CM et al.: Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003; 34: 1431-6.
36. MUNIYAPPA R, LEE S, CHEN H, QUON MJ: Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-26.
37. LORENZO C, HAFFNER SM, STANCAKOVA A, KUUSISTO J, LAAKSO M: Fasting and OGTTderived measures of insulin resistance as compared with the euglycemic-hyperinsulinemic clamp in nondiabetic Finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab 2015; 100: 544-50.
38. WESTHOVENS R, NIJS J, TAELMAN V, DEQUEKER J: Body composition in rheumatoid arthritis. Br J Rheumatol 1997; 36: 444-8.
39. ABOUASSI H, TUNE KN, GILMORE B et al.: Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis. J Rheumatol 2014; 41: 1974-9.
40. LORENZO C, HAZUDA HP, HAFFNER SM: Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab 2012; 97: 793-9.
41. HERTLE E, VAN GREEVENBROEK MM, STEHOUWER CD: Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia 2012; 55: 881-4.
42. HERTLE E, van GREEVENBROEK MM, ARTS IC et al.: Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease. The CODAM study. Thromb Haemost 2014; 111: 1102-11.
43. van GREEVENBROEK MM, JACOBS M, van der KALLEN CJ et al.: Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM study). Int J Cardiol 2012; 154: 158-62.
44. WLAZLO N, van GREEVENBROEK MM, FERREIRA I et al.: Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care 2014; 37: 1900-9.
45. TORRES T, BETTENCOURT N, MENDONCA D, VASCONCELOS C, SILVA BM, SELORES M: Complement C3 as a marker of cardiometabolic risk in psoriasis. Arch Dermatol Res 2014; 306: 653-60.
46. DEHDASHTIHAGHIGHAT S, MEHDIZADEHKASHI A, ARBABI A, PISHGAHROUDSARI M, CHAICHIAN S: Assessment of C-reactive Protein and C3 as Inflammatory Markers of Insulin Resistance in Women with Polycystic Ovary Syndrome: A Case-Control Study. J Reprod Infertil 2013; 14: 197-201.
47. HERNANDEZ-MIJARES A, JARABO-BUENO MM, LOPEZ-RUIZ A, SOLA-IZQUIERDO E, MORILLAS-ARINO C, MARTINEZ-TRIGUERO ML: Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond) 2007; 31: 927-32.
48. NAUGHTON MA, BOTTO M, CARTER MJ, ALEXANDER GJ, GOLDMAN JM, WALPORT MJ: Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 1996; 156: 3051-6.
49. CIANFLONE K, XIA Z, CHEN LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003; 1609: 127-43.
50. WLAZLO N, van GREEVENBROEK MM, FERREIRA I et al.: Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012; 61: 1787-96.
51. VOLANAKIS JE: Transcriptional regulation of complement genes. Annu Rev Immunol 1995; 13: 277-305.
52. BALDO A, SNIDERMAN AD, St-LUCE S et al.: The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 1993; 92: 1543-7.
53. MASLOWSKA M, VU H, PHELIS S et al.: Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 1999; 29: 679-86.
54. FARAJ M, HAVEL PJ, PHELIS S, BLANK D, SNIDERMAN AD, CIANFLONE K: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-602.
55. KALANT D, MacLAREN R, CUI W et al.: C5L2 is a functional receptor for acylationstimulating protein. J Biol Chem 2005; 280: 23936-44.
56. GERMINARIO R, SNIDERMAN AD, MANUEL S, LEFEBVRE SP, BALDO A, CIANFLONE K: Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 1993; 42: 574-80.